Folgen
R. Jayachandra Babu
R. Jayachandra Babu
Sonstige NamenRamapuram Jayachandra Babu, Jayachandra Babu Ramapuram, Jay Ramapuram
Auburn University, Harrison Collge of Pharmacy
Bestätigte E-Mail-Adresse bei auburn.edu
Titel
Zitiert von
Zitiert von
Jahr
Nanomedicine scale-up technologies: feasibilities and challenges
R Paliwal, RJ Babu, S Palakurthi
Aaps Pharmscitech 15 (6), 1527-1534, 2014
3932014
Alternatives to biological skin in permeation studies: Current trends and possibilities
R Neupane, SHS Boddu, J Renukuntla, RJ Babu, AK Tiwari
Pharmaceutics 12 (2), 152, 2020
2882020
Amorphous-state characterization of efavirenz—polymer hot-melt extrusion systems for dissolution enhancement
SK Sathigari, VK Radhakrishnan, VA Davis, DL Parsons, RJ Babu
Journal of pharmaceutical sciences 101 (9), 3456-3464, 2012
1732012
Role of cyclodextrins in nanoparticle-based drug delivery systems
H Shelley, RJ Babu
Journal of pharmaceutical sciences 107 (7), 1741-1753, 2018
1662018
Physicochemical characterization of efavirenz–cyclodextrin inclusion complexes
S Sathigari, G Chadha, YHP Lee, N Wright, DL Parsons, VK Rangari, ...
Aaps Pharmscitech 10, 81-87, 2009
1262009
Resveratrol‐loaded nanomedicines for cancer applications
M Annaji, I Poudel, SHS Boddu, RD Arnold, AK Tiwari, RJ Babu
Cancer reports 4 (3), e1353, 2021
1252021
Formulation of controlled release gellan gum macro beads of amoxicillin
RJ Babu, S Sathigari, MT Kumar, JK Pandit
Current drug delivery 7 (1), 36-43, 2010
1232010
In vitro and in vivo evaluation of topical formulations of spantide II
L Kikwai, RJ Babu, R Prado, A Kolot, CA Armstrong, JC Ansel, M Singh
Aaps Pharmscitech 6, E565-E572, 2005
1182005
Biomaterial‐Derived Calcium Carbonate Nanoparticles for Enteric Drug Delivery
D Render, T Samuel, H King, M Vig, S Jeelani, RJ Babu, V Rangari
Journal of nanomaterials 2016 (1), 3170248, 2016
932016
Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: characterization of viscosity, in vitro drug release, droplet size …
P Dayal, V Pillay, RJ Babu, M Singh
Aaps Pharmscitech 6, E573-E585, 2005
922005
Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems
RJ Babu, JK Pandit
International journal of pharmaceutics 288 (2), 325-334, 2005
922005
Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin
RJ Babu, JK Pandit
International journal of pharmaceutics 271 (1-2), 155-165, 2004
922004
Formulation and in vitro evaluation of transdermal patches of melatonin
N Kanikkannan, S Andega, S Burton, RJ Babu, M Singh
Drug development and industrial pharmacy 30 (2), 205-212, 2004
922004
Therapeutic potential and utility of elacridar with respect to P-glycoprotein inhibition: an insight from the published in vitro, preclinical and clinical studies
RP Dash, R Jayachandra Babu, NR Srinivas
European journal of drug metabolism and pharmacokinetics 42, 915-933, 2017
902017
Lipid materials for topical and transdermal delivery of nanoemulsions
KR Pawar, RJ Babu
Critical Reviews™ in Therapeutic Drug Carrier Systems 31 (5), 2014
802014
Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro
L Kikwai, N Kanikkannan, RJ Babu, M Singh
Journal of controlled release 83 (2), 307-311, 2002
782002
Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics
RP Dash, RJ Babu, NR Srinivas
Clinical pharmacokinetics 57, 1385-1398, 2018
742018
Critical assessment of pharmacokinetic drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid …
V Veeravalli, RP Dash, JA Thomas, RJ Babu, LMV Madgula, NR Srinivas
Drug safety 43, 711-725, 2020
632020
Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin
RJ Babu, JK Pandit
Drug Delivery 12 (3), 165-169, 2005
632005
Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 …
RP Dash, RJ Babu, NR Srinivas
Xenobiotica 48 (1), 89-108, 2018
622018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20